AKBA (Akebia Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

AKBA (Akebia Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

Mkt Cap$365M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$236M

Net Income (TTM)-$5M

EPS (TTM)-$0.02

Free Cash Flow (TTM)$68M

Gross Margin83.3%

Op. Margin9.9%

Net Margin-2.3%

FCF Margin28.6%

P/S Ratio (TTM)1.5x

P/E Ratio (TTM)—

YoY Rev Growth+47.5%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$40M	$20M	-$26M
Q2 23	$56M	$39M	-$9M
Q3 23	$42M	$24M	-$13M
Q4 23	$56M	$38M	$1M
Q1 24	$33M	$30M	-$15M
Q2 24	$44M	$35M	-$9M
Q3 24	$37M	$23M	-$13M
Q4 24	$46M	$26M	-$14M
Q1 25	$57M	$50M	$14M
Q2 25	$62M	$53M	$14M
Q3 25	$59M	$49M	$4M
Q4 25	$58M	$45M	-$9M

Valuation

Quarter	P/S	P/E
Q1 23	1.4x	—
Q2 23	1.8x	—
Q3 23	1.9x	—
Q4 23	1.9x	—
Q1 24	2.0x	—
Q2 24	2.1x	—
Q3 24	2.1x	—
Q4 24	2.3x	—
Q1 25	2.0x	—
Q2 25	1.8x	—
Q3 25	1.6x	—
Q4 25	1.5x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$18M	-$18M
Q2 23	$4M	$4M
Q3 23	-$7M	-$7M
Q4 23	-$2M	-$2M
Q1 24	-$19M	-$19M
Q2 24	-$10M	-$10M
Q3 24	-$7M	-$7M
Q4 24	-$4M	-$4M
Q1 25	-$14M	-$14M
Q2 25	$22M	$22M
Q3 25	$28M	$28M
Q4 25	$31M	$31M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$0
Q1 24	$0
Q2 24	$29K
Q3 24	$2K
Q4 24	$2K
Q1 25	$18K
Q2 25	$126K
Q3 25	$77K
Q4 25	$162K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	-35.2%	-45.4%
Q2 23	-55.4%	-29.2%
Q3 23	-13.7%	-44.4%
Q4 23	+1.8%	-10.9%
Q1 24	-18.5%	-27.5%
Q2 24	-22.6%	-19.9%
Q3 24	-11.0%	-9.3%
Q4 24	-17.3%	+10.9%
Q1 25	+75.8%	-7.8%
Q2 25	+43.1%	-7.6%
Q3 25	+57.0%	+8.8%
Q4 25	+23.9%	+8.8%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$2M	6.2%
Q2 23	$3M	6.2%
Q3 23	$2M	4.3%
Q4 23	$2M	2.7%
Q1 24	$2M	7.2%
Q2 24	$2M	4.7%
Q3 24	$2M	4.4%
Q4 24	$0	0.0%
Q1 25	$2M	3.8%
Q2 25	$3M	4.3%
Q3 25	$3M	5.5%
Q4 25	$3M	5.6%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 23	$20M	—	$25M	—
Q2 23	$20M	—	$27M	—
Q3 23	$13M	—	$23M	—
Q4 23	$10M	—	$25M	—
Q1 24	$10M	—	—	—
Q2 24	$8M	—	—	—
Q3 24	$8M	—	—	$27M
Q4 24	$12M	$23M	$5M	—
Q1 25	$10M	—	—	$26M
Q2 25	$11M	—	—	$27M
Q3 25	$15M	—	—	$30M
Q4 25	$27M	—	—	$26M

Revenue Segments

Quarter	License Collaboration And Other Revenue	Product
Q1 23	$5M	$35M
Q2 23	$14M	$42M
Q3 23	$2M	$40M
Q1 24	$2M	$31M
Q2 24	$2M	$41M
Q3 24	$2M	$36M
Q1 25	$2M	$56M
Q2 25	$2M	$60M
Q3 25	$2M	$57M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$57M	$0	$57M
Q2 23	$54M	$0	$54M
Q3 23	$47M	$0	$47M
Q4 23	$43M	$0	$43M
Q1 24	$42M	$0	$42M
Q2 24	$39M	$0	$39M
Q3 24	$34M	$0	$34M
Q4 24	$52M	$0	$52M
Q1 25	$113M	$0	$113M
Q2 25	$137M	$0	$137M
Q3 25	$166M	$0	$166M
Q4 25	$185M	$0	$185M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	185M	+0.4%
Q2 23	187M	+1.1%
Q3 23	188M	+0.8%
Q4 23	190M	+1.2%
Q1 24	205M	+7.6%
Q2 24	210M	+2.3%
Q3 24	210M	+0.3%
Q4 24	219M	+4.0%
Q1 25	242M	+10.5%
Q2 25	271M	+12.2%
Q3 25	274M	+1.2%
Q4 25	265M	-3.3%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	$0	43
FY 15	$0	64
FY 16	$17K	90
FY 17	$2M	114
FY 18	$639K	325
FY 19	$931K	360
FY 20	$775K	380
FY 21	$497K	426
FY 22	$1M	205
FY 23	$1M	167
FY 24	$885K	181
FY 25	$6K	40K